Pluto Biosciences, Inc

MV-4-11 or THP-1 cells treated with LSD1 inhibitor INCB059872 (GSE145106)

Bulk RNA sequencing

INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. LSD1 inhibition can induce differentiation of acute myeloid leukemia (AML), and here we have used RNA-seq to measure the transcriptional changes caused by INCB059872 in two AML cell lines. PI: Scott Hiebert Vanderbilt University

View this experiment on Pluto Biosciences, Inc